肿瘤治疗相关心脏损伤诊断的研究进展

The diagnosis of cancer therapeutics-related cardiac dysfunction

心脏损伤是胸部肿瘤放疗后或使用心脏毒性药物化疗后常见且严重的并发症。随着肿瘤治疗手段的改进以及药物的开发,患者总生存时间延长,很大一部分癌症患者带瘤生存甚至达到治愈,肿瘤治疗相关心脏损伤(CTRCD)的发生率和死亡率明显增高,严重影响着肿瘤患者的生存时间及生活质量。但是目前对于肿瘤治疗相关的心脏损伤尚无特异的标准或指南,尚难与原发性心脏疾病相鉴别。文章主要就肿瘤相关治疗后引起CTRCD的临床表现及诊断方法进行综述。

Cardiac dysfunction is a common and severe side-effect after cancer therapy including thoracic radiation or cytotoxic agents.With the development of the cancer therapy method and the agents,the survival time of the patients has improved while most cancer patients could live with tumor or even be cured.The rate of cancer therapeutics-related cardiac dysfunction have obviously increased which seriously affect the time and life quality of patients with tumor.But there are no authoritative consensus criteria or guideline to diagnose CTRCD at present while it is difficult to identify CTRCD with primary heart disease.In this article,we summarized some diagnosis methods which could identify early CTRCD,and then we may give early drug intervention as soon as possible to reduce the incidence and remission rate of cardiovascular events.